Abstract: TH-PO1116
Neutrophil/Lymphocyte Ratio in Prediction of Disease Progression in Patients with Stage 1-4 CKD in China: Results from the Chinese Cohort Study of CKD (C-STRIDE)
Session Information
- CKD: Clinical, Outcomes, Trials - I
October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Yuan, Qiongjing, Xiangya Hospital, Central South University, Changsha, China
- Wang, Jinwei, Renal Division, Department of Medicine, Peking University First Hospital; Peking University Institute of Nephrology, Beijing, BEIJING, China
- Xu, Hui, Nephrology Department, Xiangya Hospital, Central South University, Changsha, Hunan, China, ChangSha, China
Group or Team Name
- the C-STRIDE study group
Background
Chronic kidney disease (CKD) leads to end-stage renal failure and cardiovascular events. An attribute to these progressions is abnormalities in inflammation, which can be evaluated using the neutrophil/lymphocyte (N/L) ratio. We aimed to investigate the association of N/L ratio with the progression of ESKD, CVD and all-cause mortality in Chinese patients with stages 1-4 CKD.
Methods
A total of 1341 stages 1-4 CKD (18–74 years of age) patients with complete N/L and other relevant clinical variables were included in the current analysis. . Patients were divided according to the median of baseline N/L ratio (≥2.26 or <2.26). ESKD was defined at time to start hemodialysis, peritonal dialysis or renal transplantation. CVD risk was determined with onset of new CVD events. All-cause mortality was recorded at time of decease. The follow-up was censored at June 30, 2017. Cox regression analysis was used in estimating the association between N/L and the outcomes.
Results
Baseline N/L ratio was related to anemia rate, total serum cholesterol, eGFR, blood pressure, uric acid, CKD-MBD rate, cardiovascular disease, ACR and metabolic acidosis. The study duration was 4.35 year(IQR 2.86-5.26). Patients with N/L ratio ≥2.26 were at risk of developing ESKD (HR 1.687(95% CI:1.288,2.209))and all-cause mortality (HR 3.220(95% CI:1.174,8.834))compared to patients with N/L ratio ＜2.26 (P<0.05); We did not observe a significant association between abnormal N/L and CVD risk in the multi-variable adjusted model.
Conclusion
Our results suggest that N/L ratio other than hs-CRP is associated with the risk of ESKD and all-cause mortality in Chinese patients with stage1-4 CKD. N/L ratio is an easily accessible and useful marker for monitoring CKD patients in clinical practice.
Funding
- Government Support - Non-U.S.